Wsd Medi Clinical Sp. z o.o.

Warsaw 22 trials 9 recruiting

22 Registered trials

9 Currently recruiting

Organisation

Wsd Medi Clinical Sp. z o.o.

Location

Warsaw, Poland

Identifier

ORG-100048655

Address

Aleja Jana Rodowicza Anody 22, 02-786, Poland

Departments

Mediclinical
N/A
NA
Site Name: WSD MEDI/ Site Address: Al. Jana Rodowicza "Anody" 22/U4, 02-786 Warszawa
TBC
WSD MEDI

Clinical trials at this site (22)

Search interface

A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending

2025-521037-86-00 Immune system diseases 5
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti… Pending

2025-521038-27-00 Immune system diseases 5
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending

2025-522855-25-00 Carcinoma, Transitional Cell 5
LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study Recruiting

2025-522338-30-00 Ulcerative Colitis 4 2026-03-31
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting

2025-521036-11-00 Immune system disseases 5 2026-03-23
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting

2025-521035-37-00 Immune system diseases 5 2026-03-02
Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2025-521382-27-00 Moderately to Severely Active Crohn's Disease 10 2025-12-04
Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting

2025-521381-10-00 Moderately to Severely Active Ulcerative Colitis 5 2025-12-03
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting

2025-521242-26-00 Moderately to Severely Active Ulcerative Colitis 4 2025-11-27
A Study to Assess the Efficacy, Safety, and what the body does to RO7837195 in Participants with Moderately to Severely Active Ulcerative Co… Recruiting

2025-520690-39-00 Moderately to Severely Active Ulcerative Colitis (UC) 4 2025-11-04
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici… Recruiting

2024-516219-25-00 psoriatic arthritis 5 2025-03-25
A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease Recruiting

2023-508158-24-00 Moderately to Severely Active Crohn’s Disease 4 2024-06-25
Proof of Concept trial with CIT-013 in Rheumatoid Arthritis Ended

2024-517356-35-00 Moderately Active Rheumatoid Arthritis 4 2025-07-29
A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended

2024-518998-33-00 Ulcerative Colitis 5 2025-07-23
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended

2024-512925-95-00 Advanced/Metastatic Breast Cancer 5 2025-05-16
Crohn's Disease: Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn’s Disease Ended

2024-516023-13-00 Crohn's disease 5 2025-01-23
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended

2024-515027-11-00 Crohn’s disease 4 2023-06-29
Dose-finding study of SAR443122 in adult participants with ulcerative colitis Ended

2022-500290-14-01 Colitis ulcerative 4 2023-05-11
Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis Ended

2023-508679-34-00 Ulcerative Colitis 4 2024-07-30
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis Ended

2023-506655-19-00 Ulcerative Colitis (UC) 4 2024-05-16
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended

2024-511089-36-00 Crohn’s disease 4 2023-03-17